Mabion S.A.

Warsaw Stock Exchange MAB.WA

Mabion S.A. Capital Expenditure for the year ending December 31, 2023: USD -9.64 M

Mabion S.A. Capital Expenditure is USD -9.64 M for the year ending December 31, 2023, a -152.33% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Mabion S.A. Capital Expenditure for the year ending December 31, 2022 was USD -3.82 M, a 51.17% change year over year.
Mabion S.A. Capital Expenditure for the year ending December 31, 2021 was USD -7.82 M, a -769.14% change year over year.
Mabion S.A. Capital Expenditure for the year ending December 31, 2020 was USD -899.84 K, a 62.88% change year over year.
Mabion S.A. Capital Expenditure for the year ending December 31, 2019 was USD -2.42 M, a -32.56% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Warsaw Stock Exchange: MAB.WA

Mabion S.A.

CEO	Mr. Krzysztof Kaczmarczyk
IPO Date	Aug. 10, 2010
Location	Poland
Headquarters	ul. gen. Mariana Langiewicza 60
Employees	241
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics

Description

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.

Key trends

Past 5 years